Pharming Group N.V. (LON:0QCO)

Market Cap	518.02M
Revenue (ttm)	248.22M
Net Income (ttm)	-10.92M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,311
Average Volume	125,632
Open	0.8748
Previous Close	0.8790
Day's Range	0.8615 - 0.8785
52-Week Range	0.6500 - 1.0970
Beta	0.54
RSI	44.12
Earnings Date	Jul 31, 2025

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 404
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCO

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Financial numbers in USD